# A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

> **NCT03083704** · PHASE1 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 153 (actual)

## Conditions studied

- Bleeding

## Interventions

- **BIOLOGICAL:** Andexanet alfa (Gen 1 Process 2)
- **DRUG:** Apixaban 5 MG
- **DRUG:** Rivaroxaban 20 MG
- **DRUG:** Enoxaparin sodium
- **DRUG:** Edoxaban 60 MG
- **BIOLOGICAL:** Andexanet alfa (Gen 2)
- **BIOLOGICAL:** Andexanet alfa (Gen 1 Process 3)
- **DRUG:** Apixaban 10 MG
- **DRUG:** Rivaroxaban 10 MG

## Key facts

- **NCT ID:** NCT03083704
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-26
- **Primary completion:** 2017-09-28
- **Final completion:** 2017-09-28
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03083704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03083704, "A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03083704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*